登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于2024年12月13日召开第九届董事 会第五次（临时）会议及2024年12月30日召开2024年第六次临时股东大会，审议通过《关于公司及下属 子公司申请融资额度并提供担保的议案》，同意公司及部分下属子公司2025年度为公司及合并报表范围 内的子公司提供担保额度累计不超过人民币49亿元。具体内容详见公司于2024年12月14日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于公司及下属子公司申请融资额度并提供担保的公告》（公告编 号：2024-111）。 二、进展情况 近日，公司与兴业银行股份有限公司北京中关村支行（以下简称"兴业银行"）签署了《最高额保证合 同》，为慈铭健康体检管理集团有限公司（以下简称"慈铭健康"）提供最高本金限额人民币5,000万元 的连带责任担保。 公司与徽商银行股份有限公司蚌埠中荣支行（以下简称"徽商银行"）分别签署了《最高额保证合同》， 为安 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-081 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司与徽商银行股份有限公司蚌埠中荣支行（以下简称"徽商银行"）分别签 署了《最高额保证合同》，为安徽慈济医疗投资管理有限公司（以下简称"安徽慈 济"）、安徽慈铭奥亚健康管理有限公司（以下简称"安徽慈铭奥亚"）分别提供最 高债权额人民币 1,300 万元、1,300 万元的连带责任担保。 公司与北京银行股份有限公司杭州分行（以下简称"北京银行"）签署了《最 高额保证合同》，为慈铭健康体检管理集团杭州有限公司（以下简称"慈铭杭州"） 提供主债权本金最高限额人民币 1,000 万元的连带责任担保。 公司与华夏银行股份有限公司台州分行（以下简称"华夏银行"）签署了《最 高额保证合同》，为台州市美年门诊部有限公司（以下简称"台州美年"）提供最 高债权额人民币 1,000 万元的连带责任担保。 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第 1 号——主板 ...

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4433.77 points, down 0.69%, with a trading volume of 6.716 billion HKD and a turnover rate of 0.73% [1] - Among the index constituents, 18 stocks rose while 39 stocks fell, with Global Medical leading the gainers at 3.66% and Health Road leading the decliners at 6.35% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (14.56% weight, latest price 200.62, market cap 243.24 billion) [1] - Yier Eye Hospital (11.62% weight, latest price 11.50, market cap 107.24 billion) [1] - Lejin Medical (4.85% weight, latest price 15.74, market cap 29.01 billion) [1] - Aimeike (4.80% weight, latest price 145.06, market cap 43.89 billion) [1] - Yuyue Medical (4.66% weight, latest price 35.82, market cap 35.91 billion) [1] - Yingke Medical (3.64% weight, latest price 42.40, market cap 27.78 billion) [1] - Furuide (3.59% weight, latest price 67.36, market cap 17.85 billion) [1] - Meinian Health (3.58% weight, latest price 5.21, market cap 20.39 billion) [1] - Sinopharm (3.35% weight, latest price 18.63, market cap 58.14 billion) [1] - Ping An Good Doctor (2.63% weight, latest price 13.39, market cap 28.93 billion) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 83.77 million HKD, while retail investors saw a net inflow of 61.08 million HKD [1] - Specific stock capital flows include: - Mindray Medical: main fund net inflow of 37.11 million, retail net outflow of 4.23 million [2] - Yuyue Medical: main fund net inflow of 3.70 million, retail net inflow of 4.71 million [2] - Over the past 10 days, one stock was newly added to the index [2]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

最新一期业绩显示，2025年三季报，公司实现营业收入69.25亿元，同比减少3.01%；净利润5185.99万 元，同比增加110.53%，销售毛利率38.33%。 交易所数据显示，11月28日，美年健康收盘5.35元，上涨1.33%，滚动市盈率PE（当前股价与前四季度 每股收益总和的比值）达到67.67倍，总市值209.41亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13美年健康67.6774.202.65209.41亿行业平均 45.1253.233.76187.14亿行业中值60.3766.233.1874.13亿1药明康德18.1528.793.842720.89亿2华康洁净 29.6748.101.7732.14亿3普蕊斯29.9134.162.9036.36亿4凯莱英32.1935.241.93334.45亿5诺禾致源 32.5228.952.2056.98亿6爱尔眼科33.3230.164.781072.42亿7康龙化成34.0428.713.52514.79亿8诺思格 35.9238.782.8354.38亿9华厦眼科36.1037.182.66159.35亿10通策医疗36 ...

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4494.42 points, up 0.15%, with a trading volume of 7.52 billion yuan and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Medical Pulse leading the gainers at 3.65% and Health Road leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, latest price 196.30 yuan, market cap 238 billion yuan, up 1.50%) [1] - Yier Eye Hospital (11.62% weight, latest price 11.40 yuan, market cap 106.31 billion yuan, down 0.26%) [1] - Lejin Medical (4.85% weight, latest price 15.87 yuan, market cap 29.26 billion yuan, up 0.13%) [1] - Aimeike (4.80% weight, latest price 146.26 yuan, market cap 44.26 billion yuan, up 0.83%) [1] - Yuyue Medical (4.66% weight, latest price 35.70 yuan, market cap 35.79 billion yuan, down 0.67%) [1] - Yingke Medical (3.64% weight, latest price 41.53 yuan, market cap 27.21 billion yuan, up 1.94%) [1] - Furuide (3.59% weight, latest price 67.08 yuan, market cap 17.78 billion yuan, up 1.36%) [1] - Meinian Health (3.58% weight, latest price 5.28 yuan, market cap 20.67 billion yuan, down 1.68%) [1] - Sinopharm (3.35% weight, latest price 18.42 yuan, market cap 57.48 billion yuan, down 0.69%) [1] - Ping An Good Doctor (2.63% weight, latest price 13.66 yuan, market cap 29.52 billion yuan, down 1.83%) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 58.83 million yuan, while retail investors saw a net inflow of 78.07 million yuan [1] - Specific stock capital flows include: - Aimeike: Main fund net inflow of 46.99 million yuan, retail net outflow of 30.07 million yuan [2] - Mindray Medical: Main fund net inflow of 33.08 million yuan, retail net outflow of 17.11 million yuan [2] - Furuide: Main fund net inflow of 13.68 million yuan, retail net outflow of 19.08 million yuan [2] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments in the last 10 days, with one new stock added [2]

Core Insights - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4391.58 points, up 0.14%, with a trading volume of HKD 8.259 billion and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Mai Rui Medical leading the gainers at 3.65% and Jian Kang Zhi Lu leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index are as follows: - Mai Rui Medical (sz300760) holds a weight of 14.56%, latest price at HKD 196.30, with a market cap of HKD 238 billion and a gain of 1.50% [1] - Yan Er Eye Hospital (sz300015) has a weight of 11.62%, latest price at HKD 11.40, with a market cap of HKD 106.31 billion and a decline of 0.26% [1] - Le Jin Medical (sz300003) has a weight of 4.85%, latest price at HKD 15.87, with a market cap of HKD 2.93 billion and a slight gain of 0.13% [1] - Ai Mei Ke (sz300896) has a weight of 4.80%, latest price at HKD 146.26, with a market cap of HKD 44.26 billion and a gain of 0.83% [1] - Yu Yue Medical (sz002223) has a weight of 4.66%, latest price at HKD 35.70, with a market cap of HKD 35.79 billion and a decline of 0.67% [1] - Ying Ke Medical (sz300677) has a weight of 3.64%, latest price at HKD 41.53, with a market cap of HKD 27.21 billion and a gain of 1.94% [1] - Fu Rui Co., Ltd. (sz300049) has a weight of 3.59%, latest price at HKD 67.08, with a market cap of HKD 17.78 billion and a gain of 1.36% [1] - Mei Nian Health (sz002044) has a weight of 3.58%, latest price at HKD 5.28, with a market cap of HKD 20.67 billion and a decline of 1.68% [1] - China National Pharmaceutical (hk01099) has a weight of 3.35%, latest price at HKD 18.42, with a market cap of HKD 57.48 billion and a decline of 0.69% [1] - Ping An Good Doctor (hk01833) has a weight of 2.63%, latest price at HKD 13.66, with a market cap of HKD 29.52 billion and a decline of 1.83% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled HKD 58.83 million, while retail investors saw a net inflow of HKD 78.07 million [1] - The detailed capital flow for the top stocks shows: - Ai Mei Ke (300896) had a main fund net inflow of HKD 46.99 million but a retail net outflow of HKD 30.07 million [2] - Mai Rui Medical (300760) experienced a main fund net inflow of HKD 33.08 million with retail outflows [2] - Other stocks like Fu Rui Co., Ltd. (300049) and Li Bang Instruments (300206) also showed mixed capital flows with net inflows from main funds but outflows from retail investors [2] Recent Adjustments - In the past 10 days, there has been an adjustment in the Shenzhen-Hong Kong Stock Connect Medical Index, with one new stock added [2]

Core Viewpoint - Meinian Health's stock closed at 5.38 yuan on November 24, with a 3.66% increase, resulting in a rolling PE ratio of 68.05 times and a total market capitalization of 21.059 billion yuan [1] Company Summary - Meinian Health's main business is health examination services, with its primary product being health check-up services [1] - For the third quarter of 2025, Meinian Health reported revenue of 6.925 billion yuan, a year-on-year decrease of 3.01%, while net profit reached 518.599 million yuan, a year-on-year increase of 110.53%, with a gross profit margin of 38.33% [1] Industry Summary - The average PE ratio for the healthcare services industry is 44.32 times, with a median of 60.11 times, positioning Meinian Health at 31st place within the industry [1] - As of the third quarter of 2025, 22 institutions held shares in Meinian Health, including 14 funds and 8 other entities, with a total holding of 1.3443075 billion shares valued at 6.681 billion yuan [1]

Core Viewpoint - The article discusses the emergence of a new era in the anti-aging industry, driven by data and AI, as China enters a "super-aging" phase, with the market expected to exceed 4.6 trillion yuan by 2035. The key challenge has been supply, with a lack of standardized, low-threshold tools for consumers [1][4]. Demand Side - A "perfect storm" is forming on the demand side, driven by policies, demographics, and changing consumer mindsets. Policies are clearly directing the development of the anti-aging industry, while the younger demographic (ages 19-35) is becoming the main consumer group, accounting for 56.6% of anti-aging spending [4][5]. Supply Side - The traditional anti-aging sector has struggled with the challenge of measuring product value. Existing models like DNA methylation clocks and protein clocks are costly and limited in application, making it difficult to penetrate the mass market [5][6]. Technological Breakthrough - The launch of the "Hematological Clock" by Meinian Health represents a significant breakthrough, enabling the industry to transition from "concept consumption" to "data-driven" services. This product uses routine health check data to assess biological age, significantly lowering costs compared to high-end anti-aging tests [6][7]. Three Pillars of Capability - The "Hematological Clock" is built on three foundational capabilities: unprecedented data scale, non-linear algorithm philosophy, and self-evolving architecture. These elements create a strong competitive moat and long-term compounding effects [7][8][9]. Data Scale - Meinian Health's extensive real-world health data provides a robust training foundation for the "Hematological Clock," capturing aging trajectories across various demographics and lifestyles, which is crucial for precise assessments [8]. Non-linear Algorithms - The use of non-linear modeling allows the "Hematological Clock" to analyze the interrelationships between health indicators, identifying key factors driving aging, thus moving from correlation to causation [9][10]. Self-evolution - The product's architecture allows it to continuously improve its predictive capabilities based on user data, enhancing user engagement and increasing the platform's competitive edge over time [11]. Service Transformation - The "Hematological Clock" transforms the traditional health check into a long-term management service, addressing structural pain points in the industry. It creates a complete service loop of "detection-insight-intervention," allowing for personalized health management [12][15]. Revenue Models - The service offers diverse monetization opportunities, including standalone products for consumers and customized health management solutions for businesses, thus expanding the market reach [13][14]. Strategic Significance - The launch of the "Hematological Clock" marks a strategic milestone for Meinian Health, representing a shift from a single product to a sustainable profit ecosystem, crucial for growth in a competitive market [15].

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]